Boehringer Ingelheim Pharmaceuticals, Inc. Tipranavir Capsules NDA[removed]Antiviral Drugs Advisory Committee Briefing Document, April 19, 2005 Boehringer Ingelheim Pharmaceuticals, Inc.

First Page		Document Content
Date: 2005-05-18 11:35:39 Tipranavir Antiretroviral drug Ritonavir Saquinavir Lopinavir Tenofovir Enzyme inhibitor Zidovudine Efavirenz Chemistry Organic chemistry Protease inhibitors		Boehringer Ingelheim Pharmaceuticals, Inc. Tipranavir Capsules NDA[removed]Antiviral Drugs Advisory Committee Briefing Document, April 19, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 2,18 MB Share Document on Facebook

	UNITED STATES of AMERICA EXPERT HIV HEALTHCARE AHF’s path to becoming the largest provider of HIV/AIDS care in the U.S. began with a small group of dedicated activists in Los Angeles in the 1980s who had a simple DocID: 1rhxq - View Document
	Principles of collaboration SHCS_NICER_v5-1_NICER__Approved_Nov10 DocID: 1r7HF - View Document
	June 17, 2009 Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds Damilola A. Adepegba, Department of Natural Sciences, University of Maryland DocID: 1qLnJ - View Document
	Title Authors Affiliations DocID: 1qIsB - View Document
	Dormant copies of HIV mostly defective, new study shows DocID: 1qAMy - View Document